18119-24-9

Basic information

• Product Name: 6-CHLORO-8-HYDROXYQUINOLINE
• Synonyms: 6-CHLORO-8-HYDROXYQUINOLINE;8-chloroquinolin-6-ol;8-Chloro-6-hydroxyquinoline;6-Quinolinol, 8-chloro-
• CAS NO: 18119-24-9
• Molecular Formula: C9H6ClNO
• Molecular Weight: 179.60304
• Mol File: 18119-24-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 237-238 °C (decomp)(Solv: ethanol (64-17-5))
• Boiling Point: 343.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.412±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.11±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-8-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-8-HYDROXYQUINOLINE(18119-24-9)
• EPA Substance Registry System: 6-CHLORO-8-HYDROXYQUINOLINE(18119-24-9)

Safety Data

• Hazardous Substances Data: 18119-24-9(Hazardous Substances Data)

Usage

General Description

6-Chloro-8-hydroxyquinoline is a chemical compound that belongs to the class of quinoline derivatives. It is a mildly yellow solid substance with the chemical formula C9H6ClNO. 6-Chloro-8-hydroxyquinoline is commonly used as an intermediate for the synthesis of various pharmaceuticals, dyes, and other organic compounds. It possesses antimicrobial properties, and is used in the production of antiseptic and disinfectant products. Additionally, it has been researched for its potential therapeutic applications in the treatment of cancer and various microbial infections. However, it is important to handle this compound with care, as it may pose health and environmental risks if not properly managed.

Upstream product

• 796851-15-5 8-chloro-6-methoxyquinoline 
• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 56-81-5 glycerol 
• 98-95-3 nitrobenzene 
• 17609-80-2 4-amino-3-chlorophenol 

Downstream Products

• 282547-38-0 6-methoxy-8-piperazinoquinoline 
• 796851-15-5 8-chloro-6-methoxyquinoline 

Relevant articles and documents

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists

As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT 1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.

6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts

The present invention relates to hydrochloric acid salt and crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.

CRYSTALLINE FORMS OF 6-METHOXY-8-[4-(1-(5-FLUORO)-QUINOLIN-8-YL-PIPERIDIN-4-YL)-PIPERAZIN-1-YL]-QUINOLINE

The present invention relates to crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.